Sorrento Therapeutics (SRNE) Upgraded to “Hold” by BidaskClub
BidaskClub upgraded shares of Sorrento Therapeutics (NASDAQ:SRNE) from a sell rating to a hold rating in a research report report published on Wednesday.
A number of other analysts also recently weighed in on the company. HC Wainwright set a $20.00 target price on Sorrento Therapeutics and gave the stock a buy rating in a research report on Wednesday, August 30th. Oppenheimer set a $6.00 target price on Sorrento Therapeutics and gave the stock a buy rating in a research report on Wednesday, November 15th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Sorrento Therapeutics has an average rating of Buy and a consensus price target of $11.50.
Sorrento Therapeutics (SRNE) traded down $0.33 during trading hours on Wednesday, reaching $3.37. The company had a trading volume of 2,642,600 shares, compared to its average volume of 877,818. Sorrento Therapeutics has a one year low of $1.50 and a one year high of $6.08. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.18.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.